The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "iScience"
DOI: 10.1016/j.isci.2022.103881
Abstract: Summary Mutations in RAS pathway genes are highly prevalent in acute lymphoblastic leukemia (ALL). However, the effects of RAS mutations on ALL cell growth have not been experimentally characterized, and effective RAS-targeting therapies are being… read more here.
Keywords: kras g12d; g12d mutation; acute lymphoblastic; lymphoblastic leukemia ... See more keywords
Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.
Sign Up to like & getrecommendations! Published in 2022 at "Human molecular genetics"
DOI: 10.1093/hmg/ddac169
Abstract: Somatic activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations have been reported in patients with arteriovenous malformations. By producing LSL-Kras (G12D); Cdh5 (PAC)-CreERT2 [iEC-Kras (G12D*)] mice, we hoped to activate KRAS within vascular endothelial… read more here.
Keywords: kras induced; kras g12d; trametinib; iec kras ... See more keywords
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/9426623
Abstract: Background Kirsten rat sarcoma (KRAS) protein is an essential contributor to the development of pancreatic ductal adenocarcinoma (PDAC). KRAS G12D and G12V mutant tumours are significant challenges in cancer therapy due to high resistance to… read more here.
Keywords: kras g12d; ato; combination; drug combination ... See more keywords
Abstract C058: Vitamin C preferentially induces growth inhibition and cell death in KRAS G12D-mutant pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-c058
Abstract: Vitamin C (L-Ascorbic acid, VC), an anti-oxidant has been studied as the possible potent chemotherapeutic drug in various cancers including colorectal cancer, breast cancer, ovarian cancer, prostate cancer and lung cancer. In particular, it is… read more here.
Keywords: growth; kras g12d; cancer cells; cancer ... See more keywords
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5735
Abstract: KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found in approximately 34% of patients with pancreatic ductal adenocarcinoma… read more here.
Keywords: inhibition; antitumor; kras g12d; g12d mutated ... See more keywords
Abstract A033: KRAS codon 12 oncogenic mutations modulate protein conformation within the Switch II/Helix3 pocket
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a033
Abstract: Up to 30% of cancers harbor activating mutations in one of three RAS genes, HRAS, NRAS, or KRAS, that drive uncontrolled cellular proliferation, alter cellular metabolism, movement, differentiation, and promote cell survival and tumor immune… read more here.
Keywords: kras g12c; kras g12d; conformation; within switch ... See more keywords
The overexpression of cytochrome c oxidase subunit 6C activated by Kras mutation is related to energy metabolism in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2018 at "Translational cancer research"
DOI: 10.21037/19963
Abstract: Background: Kras mutation is frequently detected in pancreatic cancers and leads to altered energy metabolite. Here we investigated molecule markers related with Kras mutation, which could be used as developing new target for Kras mutant… read more here.
Keywords: bxpc; cox6c; kras mutation; pancreatic cancer ... See more keywords
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1013902
Abstract: KRAS mutations are among the most commonly occurring mutations in cancer. After being deemed undruggable for decades, KRAS G12C specific inhibitors showed that small molecule inhibitors can be developed against this notorious target. At the… read more here.
Keywords: kras g12d; targeted therapies; pancreatic cancer; g12d targeted ... See more keywords
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14143320
Abstract: Simple Summary Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal cancer (CRC) seems to have a different biological behavior and therapeutic approach compared with non-KRAS mutated CRC. Except for the proven predictive significance of KRAS… read more here.
Keywords: colorectal cancer; value kras; kras mutations; kras g12d ... See more keywords
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Sign Up to like & getrecommendations! Published in 2023 at "Current Issues in Molecular Biology"
DOI: 10.3390/cimb45030137
Abstract: The KRAS G12D mutation is very frequent in many cancers, such as pancreatic, colon and lung, and has remained undruggable for the past three decades, due to its smooth surface and lack of suitable pockets.… read more here.
Keywords: kras g12d; bioflavonoids potential; dietary bioflavonoids; g12d mutant ... See more keywords
Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23031309
Abstract: Owing to several mutations, the oncogene Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is activated in the majority of cancers, and targeting it has been pharmacologically challenging. In this study, using an in silico… read more here.
Keywords: g12d inhibitors; molecular docking; kras g12d; pharmacophore model ... See more keywords